Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Lascombe

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 18, 2016
Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cellsAdeline Péchery, Sylvie Fauconnet, Hugues Bittard, et al.
International Journal of Cancer|January 26, 2010
Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cellsMarie Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, et al.
Plos One|December 17, 2011
The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAILMarie-Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, et al.
Cellular Signalling|November 1, 2013
The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanismEmmanuelle Roche, Isabelle Lascombe, Hugues Bittard, et al.
Molecular and Cellular Biochemistry|June 11, 2020
Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposureCéline Elie-Caille, Isabelle Lascombe, Adeline Péchery, et al.
Cells|April 26, 2024
GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer CellsAlexandre Barbaud, Isabelle Lascombe, Adeline Péchery, et al.
Oncotarget|January 4, 2018
Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cellsMarie-Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
N-cadherin as a novel prognostic marker of progression in superficial urothelial tumorsIsabelle Lascombe, Anne Clairotte, Sylvie Fauconnet, et al.
The Journal of Biological Chemistry|May 1, 2002
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cellsSylvie Fauconnet, Isabelle Lascombe, Eric Chabannes, et al.
International Journal of Cancer|December 31, 2008
A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cellsGuillaume Boiteux, Isabelle Lascombe, Emmanuelle Roche, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 18, 2016
Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cellsAdeline Péchery, Sylvie Fauconnet, Hugues Bittard, et al.
International Journal of Cancer|January 26, 2010
Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cellsMarie Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, et al.
Plos One|December 17, 2011
The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAILMarie-Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, et al.
Cellular Signalling|November 1, 2013
The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanismEmmanuelle Roche, Isabelle Lascombe, Hugues Bittard, et al.
Molecular and Cellular Biochemistry|June 11, 2020
Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposureCéline Elie-Caille, Isabelle Lascombe, Adeline Péchery, et al.
Cells|April 26, 2024
GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer CellsAlexandre Barbaud, Isabelle Lascombe, Adeline Péchery, et al.
Oncotarget|January 4, 2018
Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cellsMarie-Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
N-cadherin as a novel prognostic marker of progression in superficial urothelial tumorsIsabelle Lascombe, Anne Clairotte, Sylvie Fauconnet, et al.
The Journal of Biological Chemistry|May 1, 2002
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cellsSylvie Fauconnet, Isabelle Lascombe, Eric Chabannes, et al.
International Journal of Cancer|December 31, 2008
A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cellsGuillaume Boiteux, Isabelle Lascombe, Emmanuelle Roche, et al.
Pageof 2